MB101 / Mustbio - LARVOL DELTA

Domestic biotech takes strides in developing multi-antibody anticancer drugs with differentiated platform [Google translation] (HIT News) - "According to the bio industry on the 26th, Must Bio, Arcgen Biosciences, and Cyron Therapeutics are working to develop multiple antibody-based immunotherapy drugs....A Must Bio official said, 'We are developing four pipelines. The company's most advanced pipeline is MB101 (development code name),' adding, 'We are continuously working to establish partnerships in various R&D and business areas.'"

Licensing / partnership • Oncology • Solid Tumor

MB101, a novel PD-L1 x CD3 targeted bispecific antibody, exhibits potent tumor-killing efficacy with minimal off-tumor toxicity (AACR 2023) - "In addition, MB101 showed superior tumor growth inhibition (TGI=70%) than that of avelumab (TGI=44%) in humanized mouse xenograft model. In summary, MB101 selectively triggers robust PD-L1-dependent tumor cytotoxicity while inducing very low cytokine release, suggesting that MB101 might be a promising therapeutic option as CD3-based bsAb for cancer treatment."

Clinical • IO biomarker • Oncology